SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
1 - 33 . (canceled)
34 . A composition comprising a crystalline solid form of Compound 1:
and a pharmaceutically acceptable carrier or excipient, wherein:
the crystalline solid form of Compound 1 is unsolvated and is Form A, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.73, about 18.30, about 18.96 and about 25.48 degrees 2-theta; or
the crystalline solid form of Compound 1 is unsolvated and is Form B, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 10.67, about 12.21, about 18.11, about 19.24 and about 21.53 degrees 2-theta; or
the crystalline solid form of Compound 1 is a dimethylformamide solvate and is Form C, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 16.32, about 18.82, about 20.26, about 22.58 and about 25.36 degrees 2-theta; or
the crystalline solid form of Compound 1 is a 1,4-dioxane solvate and is Form D, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 18.40, about 19.31, about 20.14, about 20.53 and about 25.25 degrees 2-theta; or
the crystalline solid form of Compound 1 is a methyl ethyl ketone solvate and is Form E, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 5.78, about 12.57, about 15.34, about 19.10 and about 24.80 degrees 2-theta; or
the crystalline solid form of Compound 1 is a N-methyl-2-pyrrolidone solvate and is Form F, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 15.51, about 16.86, about 18.80, about 20.97 and about 23.32 degrees 2-theta; or
the crystalline solid form of Compound 1 is a N-methyl-2-pyrrolidone solvate and is Form G, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.79, about 17.86, about 19.43, about 19.98 and about 22.35 degrees 2-theta; or
the crystalline solid form of Compound 1 is a hydrate and is Form H, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 10.82, about 11.08, about 18.45, about 22.85 and about 25.06 degrees 2-theta; or
the crystalline solid form of Compound 1 is a hydrate and is Form I, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.13, about 12.22, about 15.91, about 18.35, about 18.88, and about 21.90 degrees 2-theta.
35 . The composition of claim 34 , wherein the crystalline solid form of Compound 1 is unsolvated and is Form A, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.73, about 18.30, about 18.96 and about 25.48 degrees 2-theta.
36 . The composition of claim 34 , wherein the crystalline solid form of Compound 1 is unsolvated and is Form B, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 10.67, about 12.21, about 18.11, about 19.24 and about 21.53 degrees 2-theta.
37 . The composition of claim 34 , wherein the crystalline solid form of Compound 1 is a dimethylformamide solvate and is Form C, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 16.32, about 18.82, about 20.26, about 22.58 and about 25.36 degrees 2-theta.
38 . The composition of claim 34 , wherein the crystalline solid form of Compound 1 is a 1,4-dioxane solvate and is Form D, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 18.40, about 19.31, about 20.14, about 20.53 and about 25.25 degrees 2-theta.
39 . The composition of claim 34 , wherein the crystalline solid form of Compound 1 is a methyl ethyl ketone solvate and is Form E, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 5.78, about 12.57, about 15.34, about 19.10 and about 24.80 degrees 2-theta.
40 . The composition of claim 34 , wherein the crystalline solid form of Compound 1 is a N-methyl-2-pyrrolidone solvate and is Form F, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 15.51, about 16.86, about 18.80, about 20.97 and about 23.32 degrees 2-theta.
41 . The composition of claim 34 , wherein the crystalline solid form of Compound 1 is a N-methyl-2-pyrrolidone solvate and is Form G, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.79, about 17.86, about 19.43, about 19.98 and about 22.35 degrees 2-theta.
42 . The composition of claim 34 , wherein the crystalline solid form of Compound 1 is a hydrate and is Form H, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 10.82, about 11.08, about 18.45, about 22.85 and about 25.06 degrees 2-theta.
43 . The composition of claim 34 , wherein the crystalline solid form of Compound 1 is a hydrate and is Form I, characterized by having one or more peaks in its X-ray powder diffraction pattern selected from those at about 6.13, about 12.22, about 15.91, about 18.35, about 18.88, and about 21.90 degrees 2-theta.